TY - JOUR
T1 - Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients
T2 - A Systematic Review and Meta-Analysis
AU - Zhang, Hua
AU - Han, Han
AU - He, Tianhui
AU - Labbe, Kristen E.
AU - Hernandez, Adrian V.
AU - Chen, Haiquan
AU - Velcheti, Vamsidhar
AU - Stebbing, Justin
AU - Wong, Kwok Kin
N1 - Publisher Copyright:
© 2020 The Author(s). Published by Oxford University Press. All rights reserved.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Background: Previous studies have indicated coronavirus disease 2019 (COVID-19) patients with cancer have a high fatality rate. Methods: We conducted a systematic review of studies that reported fatalities in COVID-19 patients with cancer. A comprehensive meta-analysis that assessed the overall case fatality rate and associated risk factors was performed. Using individual patient data, univariate and multivariable logistic regression analyses were used to estimate odds ratios (OR) for each variable with outcomes. Results: We included 15 studies with 3019 patients, of which 1628 were men; 41.0% were from the United Kingdom and Europe, followed by the United States and Canada (35.7%), and Asia (China, 23.3%). The overall case fatality rate of COVID-19 patients with cancer measured 22.4% (95% confidence interval [CI] = 17.3% to 28.0%). Univariate analysis revealed age (OR = 3.57, 95% CI = 1.80 to 7.06), male sex (OR = 2.10, 95% CI = 1.07 to 4.13), and comorbidity (OR = 2.00, 95% CI = 1.04 to 3.85) were associated with increased risk of severe events (defined as the individuals being admitted to the intensive care unit, or requiring invasive ventilation, or death). In multivariable analysis, only age greater than 65 years (OR = 3.16, 95% CI = 1.45 to 6.88) and being male (OR = 2.29, 95% CI = 1.07 to 4.87) were associated with increased risk of severe events. Conclusions: Our analysis demonstrated that COVID-19 patients with cancer have a higher fatality rate compared with that of COVID-19 patients without cancer. Age and sex appear to be risk factors associated with a poorer prognosis.
AB - Background: Previous studies have indicated coronavirus disease 2019 (COVID-19) patients with cancer have a high fatality rate. Methods: We conducted a systematic review of studies that reported fatalities in COVID-19 patients with cancer. A comprehensive meta-analysis that assessed the overall case fatality rate and associated risk factors was performed. Using individual patient data, univariate and multivariable logistic regression analyses were used to estimate odds ratios (OR) for each variable with outcomes. Results: We included 15 studies with 3019 patients, of which 1628 were men; 41.0% were from the United Kingdom and Europe, followed by the United States and Canada (35.7%), and Asia (China, 23.3%). The overall case fatality rate of COVID-19 patients with cancer measured 22.4% (95% confidence interval [CI] = 17.3% to 28.0%). Univariate analysis revealed age (OR = 3.57, 95% CI = 1.80 to 7.06), male sex (OR = 2.10, 95% CI = 1.07 to 4.13), and comorbidity (OR = 2.00, 95% CI = 1.04 to 3.85) were associated with increased risk of severe events (defined as the individuals being admitted to the intensive care unit, or requiring invasive ventilation, or death). In multivariable analysis, only age greater than 65 years (OR = 3.16, 95% CI = 1.45 to 6.88) and being male (OR = 2.29, 95% CI = 1.07 to 4.87) were associated with increased risk of severe events. Conclusions: Our analysis demonstrated that COVID-19 patients with cancer have a higher fatality rate compared with that of COVID-19 patients without cancer. Age and sex appear to be risk factors associated with a poorer prognosis.
KW - Asia/epidemiology
KW - COVID-19/epidemiology
KW - Canada/epidemiology
KW - Comorbidity
KW - Europe/epidemiology
KW - Female
KW - Humans
KW - Male
KW - Neoplasms/epidemiology
KW - Risk Factors
KW - SARS-CoV-2/physiology
KW - Survival Rate
KW - United Kingdom/epidemiology
KW - United States/epidemiology
UR - http://www.scopus.com/inward/record.url?scp=85104047305&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/64dfd98a-cc1a-3a35-8c0d-57c868b26b75/
U2 - 10.1093/jnci/djaa168
DO - 10.1093/jnci/djaa168
M3 - Artículo de revisión
C2 - 33136163
AN - SCOPUS:85104047305
SN - 0027-8874
VL - 113
SP - 371
EP - 380
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 4
ER -